Logo
Thursday, 24 September 2020
Logo
The News and Media Division of The Insight Partners
Thursday, 25 Jun 2020 03:00 pm

Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158

Artax Biopharma is poised to enter clinical trials with the small molecule AX- 158, a novel approach to treat multiple autoimmune diseases without causing the immunosuppression commonly associated with current autoimmune disease therapies.

newsImage
 

Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces the formation of their Scientific Advisory Board (SAB). The SAB is comprised of experts in Immunology, Autoimmune Disease, and T Cell Signaling, and was formed to guide the company as it proceeds into future clinical trials with a first-in-class, oral small molecule autoimmune disease immunomodulator AX-158.

Artax Biopharma is poised to enter clinical trials with the small molecule AX- 158, a novel approach to treat multiple autoimmune diseases without causing the immunosuppression commonly associated with current autoimmune disease therapies.

Balbino Alarcón, PhD, Chairman of Artax's Scientific Advisory Board, commented, "I am privileged to lead Artax's Scientific Advisory Board, which mobilizes global leaders in Immunology, Autoimmune Disease, and T Cell Signaling. Collectively we are enthusiastic to collaborate on, and contribute to, important development initiatives related to Artax's innovative approach to autoimmune disease treatment."

"Artax Biopharma's Nck inhibitor AX-158 has shown impressive experimental biologic and mechanistic impact on T cell modulation - managing autoimmune disease without inducing the profound immunosuppression or interference with memory response associated with conventional or biological therapies," stated Dr. Lawrence Steinman, Stanford University Zimmerman Professor of Neurology and Neurosciences, Pediatrics, and Genetics and Scientific Advisory Board member.

"Convening a Scientific Advisory Board is a critical step as we accelerate our clinical development program," stated Artax Biopharma Chief Executive Officer Joseph Lobacki. "The clinical expertise and knowledge of these experts is unparalleled and will be instrumental in informing our development strategy across several autoimmune diseases."

The SAB will be comprised of five experts, and is being led by Professor Balbino Alarcón, PhD, co-founder of Artax Biopharma:

Tags Artax Biopharma Biotechnology Autoimmune disease Clinical trials T Cell Signaling Immunology

Neha Pandey

Aware of her elements, Neha writes the best articles across industries including electronics & semiconductors, automotive & transportation and food & beverages. Being from the finance background she has the ability to understand the dynamics of every industry and analyze the news updates to form insightful articles. Neha is an energetic person interested in music, travel, and entertainment. Since past 5 years, she written extensively on sectors like technology, finance and healthcare.


Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

media@smartmarketnews.com | sales@smartmarketnews.com

Contact Us
Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter

A PHP Error was encountered

Severity: Notice

Message: Undefined index: csrf_token

Filename: include/footer.php

Line Number: 149

Backtrace:

File: /home/smartmarketnews/public_html/application/views/include/footer.php
Line: 149
Function: _error_handler

File: /home/smartmarketnews/public_html/application/views/news_details.php
Line: 791
Function: view

File: /home/smartmarketnews/public_html/application/controllers/News_controller.php
Line: 227
Function: view

File: /home/smartmarketnews/public_html/index.php
Line: 315
Function: require_once

">
Follow Us:
© The News and Media Division of The Insight Partners 2019 | All Rights Reserved | Privacy Policy